| Symbol | SDZNY |
|---|---|
| Name | SANDOZ GROUP AG |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 4051 Switzerland Centralbahnstrasse 4 |
| Telephone | +41 61 324 11 11 |
| Fax | — |
| — | |
| Website | http://www.sandoz.com/ |
| Incorporation | CH |
| Incorporated On | 2022 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | KPMG LLP.; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: SIX Swiss Exchange |
| CIK | 0001992829 |
| Description | Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the worlds first oral penicillin in 1951, and the worlds first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion. Additional info from OTC: |
No news found.